HALO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HALO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).
Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.
Halozyme Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.
For the Biotechnology subindustry, Halozyme Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Margin of Safety % (DCF FCF Based) falls into.
Thank you for viewing the detailed overview of Halozyme Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J. Labarre | officer: SVP, Chief Technical Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Helen Torley | director, officer: President and CEO | C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Nicole Labrosse | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
James M Daly | director | INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880 |
Jeffrey William Henderson | director | 7000 CARDINAL PLACE, DUBLIN OH 43017 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
Akiko Moni Miyashita | director | 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501 |
Mark Howard Snyder | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Matsui Connie | director | 3030 CALLAN RD, SAN DIEGO CA 92121 |
Jean-pierre Bizzari | director | 235 LAUREL LN, HAVERFOLD PA 19041 |
Kenneth J Kelley | director | 1331 HILLVIEW DRIVE, MENLO PARK CA 94025 |
Elaine D Sun | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Masaru Matsuda | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Benjamin Hickey | officer: SVP, Chief Commerical Officer | C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
From GuruFocus
By PRNewswire • 10-31-2024
By PRNewswire • 11-22-2024
By GuruFocus News • 11-13-2024
By PRNewswire • 06-05-2024
By Business Wire • 09-17-2024
By GuruFocus News • 11-01-2024
By GuruFocus News • 10-03-2024
By PRNewswire • 10-24-2024
By GuruFocus Research • 08-14-2024
By PRNewswire • 08-28-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.